Technology ID
TAB-3640

SARS-CoV-2 Neutralizing Antibodies and Synthetic Nanobody Library Using a Humanized Llama Framework Region

E-Numbers
E-172-2021-0
Lead Inventor
Fleming, Bryan (NCI)
Co-Inventors
Fu, Ying (NCATS)
Renn, Alex (NCATS)
Hall, Matthew (NCATS)
Simeonov, Anton (NCATS)
Applications
Therapeutics
Research Materials
Diagnostics
Consumer Products
Therapeutic Areas
Infectious Disease
Immunology
Research Products
Antibodies
Lead IC
NCATS
ICs
NCI
NCATS
NCATS has developed a highly diverse synthetic library that will allow for the rapid identification of novel nanobodies that bind to a wide arrange of target antigens. The humanized framework used to construct the library will facilitate the transition of lead candidates into patient studies. Several highly potent SARS-CoV-2 nanobodies (antibodies) have been identified and are available for further development.

NCATS is actively seeking licensing for the 1) a synthetic library and 2) the potent neutralizing antibodies with activity against SARS-CoV-2.
Commercial Applications
  • Phage panning/Screening the nanobody library to discover novel binders
  • Optimization of SARS-CoV-2 neutralizing antibodies
Competitive Advantages
  • Highly diverse synthetic library.
  • Animal free nanobody discovery.
  • Faster turnaround time than antibody discovery requiring animal immunization.
  • Humanized framework region helps fast track therapeutics into patient trials.
Licensing Contact:
Kalsi, Jasmine
jasmine.kalsi@nih.gov